Table 1.
Target | Gene Function | Current Clinical Drugs Targeting | Protein Half-life | References |
---|---|---|---|---|
VEGFR/VEGFR2 | Angiogenesis | Sorafenib, Brivanib, Sunitinib, Cediranib, BIBF1120, Pazopanib, Regorafenib, E7080, TSU-68, Vandetanib, Ramucirumab, IMC-1121B | 70 min | [5,15,21] |
EGFR | Signal Transduction | Erlotinib, Cetuximab, Gefitinib, Lapatinib, Vandetanib | 10 h | [5,16,21] |
Bcr-ABL | Cell Proliferation | Destanib | 40 h | [5,10,17,21] |
MEK | Signal Transduction | AZD6244 | 6 h | [5,18,21] |
PDGFR | Angiogenesis/Signal Transduction | Sorafenib, Brivanib, Linifanib, BIBF1120, Pazopanib, TSU-68 | 3 h | [5,19,21] |